Wall Street brokerages expect that Otonomy Inc (NASDAQ:OTIC) will post $250,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Otonomy’s earnings. The highest sales estimate is $340,000.00 and the lowest is $150,000.00. Otonomy posted sales of $270,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 7.4%. The firm is expected to issue its next earnings results on Thursday, March 1st.
According to Zacks, analysts expect that Otonomy will report full year sales of $250,000.00 for the current year, with estimates ranging from $1.12 million to $2.20 million. For the next fiscal year, analysts forecast that the business will post sales of $8.03 million per share, with estimates ranging from $200,000.00 to $21.70 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Otonomy.
OTIC has been the topic of a number of analyst reports. Zacks Investment Research upgraded Otonomy from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Tuesday, November 14th. Piper Jaffray Companies reissued a “hold” rating and set a $8.00 target price on shares of Otonomy in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $9.15.
Several hedge funds have recently bought and sold shares of OTIC. First Manhattan Co. acquired a new position in shares of Otonomy during the 4th quarter worth approximately $10,556,000. Bank of New York Mellon Corp increased its holdings in shares of Otonomy by 72.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 596,784 shares of the biopharmaceutical company’s stock worth $1,939,000 after acquiring an additional 249,845 shares during the last quarter. Alpine Associates Management Inc. acquired a new position in shares of Otonomy during the 3rd quarter worth approximately $797,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Otonomy during the 4th quarter worth approximately $616,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Otonomy by 31.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 407,799 shares of the biopharmaceutical company’s stock worth $7,687,000 after acquiring an additional 96,630 shares during the last quarter. 67.10% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Otonomy Inc (OTIC) Will Post Quarterly Sales of $250,000.00” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/07/zacks-analysts-anticipate-otonomy-inc-otic-will-post-quarterly-sales-of-250000-00.html.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.